JP2012506402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506402A5 JP2012506402A5 JP2011532609A JP2011532609A JP2012506402A5 JP 2012506402 A5 JP2012506402 A5 JP 2012506402A5 JP 2011532609 A JP2011532609 A JP 2011532609A JP 2011532609 A JP2011532609 A JP 2011532609A JP 2012506402 A5 JP2012506402 A5 JP 2012506402A5
- Authority
- JP
- Japan
- Prior art keywords
- pramlintide
- carboxy
- carboxynonadecanoylamino
- butyryl
- his17
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003611 pramlintide Drugs 0.000 claims 70
- -1 19-carboxynonadecanoyl Chemical group 0.000 claims 66
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 52
- 101100338242 Drosophila virilis His1.1 gene Proteins 0.000 claims 17
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 claims 15
- 101150088826 arg1 gene Proteins 0.000 claims 15
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 14
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 8
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims 2
- PXVCMZCJAUJLJP-YUMQZZPRSA-N gamma-Glu-His Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 PXVCMZCJAUJLJP-YUMQZZPRSA-N 0.000 claims 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- SNPQGCDJHZAVOB-SOMABOLJSA-N D-glucosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-SOMABOLJSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- MPZWMIIOPAPAKE-BQBZGAKWSA-N Glu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N MPZWMIIOPAPAKE-BQBZGAKWSA-N 0.000 claims 1
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 claims 1
- BBBXWRGITSUJPB-YUMQZZPRSA-N Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O BBBXWRGITSUJPB-YUMQZZPRSA-N 0.000 claims 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08167154.7 | 2008-10-21 | ||
| EP08167154 | 2008-10-21 | ||
| EP09161372 | 2009-05-28 | ||
| EP09161372.9 | 2009-05-28 | ||
| PCT/EP2009/063724 WO2010046357A1 (en) | 2008-10-21 | 2009-10-20 | Amylin derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506402A JP2012506402A (ja) | 2012-03-15 |
| JP2012506402A5 true JP2012506402A5 (enExample) | 2012-12-06 |
| JP5703226B2 JP5703226B2 (ja) | 2015-04-15 |
Family
ID=41728511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532609A Active JP5703226B2 (ja) | 2008-10-21 | 2009-10-20 | アミリン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8895504B2 (enExample) |
| EP (1) | EP2340261B1 (enExample) |
| JP (1) | JP5703226B2 (enExample) |
| CN (1) | CN102197049B (enExample) |
| ES (1) | ES2662501T3 (enExample) |
| TW (1) | TW201018479A (enExample) |
| WO (1) | WO2010046357A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101400698A (zh) | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2340261B1 (en) | 2008-10-21 | 2017-12-20 | Novo Nordisk A/S | Amylin derivatives |
| EP3241558B1 (en) | 2010-09-28 | 2021-03-03 | Aegerion Pharmaceuticals, Inc. | Highly soluble leptins |
| BR112013031268B1 (pt) * | 2011-06-10 | 2020-05-12 | Novo Nordisk A/S | Polipeptídeos |
| ES2640285T3 (es) * | 2012-04-19 | 2017-11-02 | Novo Nordisk A/S | Análogos de amilina humana |
| US8575091B1 (en) | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| CN104327162A (zh) * | 2014-09-28 | 2015-02-04 | 苏州普罗达生物科技有限公司 | 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用 |
| MX2017011182A (es) | 2015-03-18 | 2018-06-06 | Zealand Pharma As | Analogos de amilina. |
| CN106554405B (zh) * | 2015-09-30 | 2020-04-24 | 深圳翰宇药业股份有限公司 | 一种多肽及其用途、制备方法 |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| CN118903386A (zh) | 2017-08-24 | 2024-11-08 | 诺和诺德股份有限公司 | Glp-1组合物及其用途 |
| JP7636321B2 (ja) * | 2018-10-11 | 2025-02-26 | インターシア セラピューティクス,インコーポレイティド | ヒトアミリンアナログペプチド及び使用方法 |
| WO2020225781A1 (en) * | 2019-05-08 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate amylin agonists and uses thereof |
| KR20220143036A (ko) | 2020-02-18 | 2022-10-24 | 노보 노르디스크 에이/에스 | 약학적 제형 |
| CR20230311A (es) * | 2020-12-16 | 2023-09-01 | Medimmune Ltd | Polipéptidos y usos de los mismos |
| TW202400632A (zh) | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| GB202217575D0 (en) * | 2022-11-24 | 2023-01-11 | Imperial College Innovations Ltd | Novel compounds |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
| US5710024A (en) * | 1996-07-23 | 1998-01-20 | Smithkline Beecham Corporation | Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44) |
| US20040022807A1 (en) * | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
| DE60324387D1 (de) * | 2002-01-08 | 2008-12-11 | Amylin Pharmaceuticals Inc | Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie |
| WO2005027978A2 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1667724A2 (en) * | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| RU2378285C2 (ru) | 2004-02-11 | 2010-01-10 | Амилин Фармасьютикалз, Инк. | Гибридные полипептиды с селектируемыми свойствами |
| WO2005097202A2 (en) | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| EA012622B1 (ru) | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки |
| WO2006005667A2 (en) | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| WO2007055728A1 (en) | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| CN101128487B (zh) | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
| AU2006230420B2 (en) * | 2005-03-31 | 2011-11-24 | Amylin Pharmaceuticals, Llc | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
| CN101400698A (zh) * | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2340261B1 (en) | 2008-10-21 | 2017-12-20 | Novo Nordisk A/S | Amylin derivatives |
-
2009
- 2009-10-20 EP EP09752134.8A patent/EP2340261B1/en active Active
- 2009-10-20 WO PCT/EP2009/063724 patent/WO2010046357A1/en not_active Ceased
- 2009-10-20 ES ES09752134.8T patent/ES2662501T3/es active Active
- 2009-10-20 CN CN200980142468.1A patent/CN102197049B/zh active Active
- 2009-10-20 JP JP2011532609A patent/JP5703226B2/ja active Active
- 2009-10-21 US US12/603,135 patent/US8895504B2/en active Active
- 2009-10-21 TW TW098135520A patent/TW201018479A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506402A5 (enExample) | ||
| JP2008533105A5 (enExample) | ||
| JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| CN114901682B (zh) | 胰岛素衍生物 | |
| JP5969461B2 (ja) | Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用 | |
| JP2013523618A5 (enExample) | ||
| RU2007134156A (ru) | Ацилированные glp-1 соединения | |
| JP2022031787A (ja) | グルカゴン及びglp-1共アゴニスト化合物 | |
| US20150133373A1 (en) | Transmucosal delivery of engineered polypeptides | |
| US20140235535A1 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2014519509A5 (enExample) | ||
| RU2007134155A (ru) | Glp-1 соединения с увеличенным временем полужизни | |
| JP2014519511A5 (enExample) | ||
| JP2011524420A5 (enExample) | ||
| JP2013523619A5 (enExample) | ||
| RU2013156937A (ru) | Полипептиды | |
| JP2014519510A5 (enExample) | ||
| JP2014516049A5 (enExample) | ||
| JP2010538049A5 (enExample) | ||
| JP2016523241A5 (enExample) | ||
| JP2012529463A (ja) | 2型糖尿病を治療するための、glp−1とfgf21との組合せ | |
| JP2012512903A5 (enExample) | ||
| JP7443315B2 (ja) | アシル化オキシントモジュリンペプチド類似体 | |
| JP2014521594A5 (enExample) | ||
| JP2018505146A (ja) | Fgf21誘導体及びその使用 |